INDICATIONS
Heart failure
- Occurs when the heart is unable to pump enough blood to the body. Fluid then accumulates in the ankles and lungs, leaving patients with shortness of breath, sapped energy and a sensation of drowning.
- Affects five million Americans.
- Costs the health care system $37 billion annually, according to the American Heart Association. Hospital care accounts for 80% of that cost.
- Is the most common cause of hospitalization for adults 65 and over. More than 25% of these patients return to the hospital within 30 days.
Acute Decompensated Heart Failure (ADHF). The most severe form of heart failure.
There are one million hospitalizations a year from acute decompensated heart failure, which Phrixus intends to target with Carmeseal.
An analysis of Medicare data published in 2010 in the New England Journal of Medicine showed that one in five patients discharged from a hospital is readmitted within 30 days. For heart-failure patients, the rate is about one in four.
Within 60 days of being discharged from hospitals up to 40% of ADHF patients are re-admitted or have died.
Duchenne Muscular Dystrophy
Duchenne is the most devastating of the muscular dystrophies. No drug is approved for the treatment of Duchenne muscular dystrophy.
- About one out of every 3,500 boys is born with the mutation for Duchenne muscular dystrophy. It affects approximately 20,000 boys and young men in the United States.
- Weakness of the heart muscle, called cardiomyopathy, occurs by age 18 in 90 percent of people with Duchenne muscular dystrophy.
- Regular monitoring of the heart (with echocardiograms) allows early detection and treatment of cardiomyopathy.
Phrixus is developing Carmeseal to treat the disease pathology independent of the genetic defect that causes the disease.